PURPOSE Prevention of chemotherapy-induced nausea and vomiting (CINV) is particularly challenging for patients receiving highly emetogenic preparative regimens before autologous stem cell transplantation (ASCT) due to the daily and continuous emetogenic stimulus of the multiple day chemotherapy. While studies have shown effective prevention of CINV during the conditioning phase with NK1 receptor antagonist (NK1RA)-containing regimens, there have been no studies evaluating antiemetic use during chemomobilization prior to ASCT. METHODS This multicenter, open-label, phase IIa study evaluated the efficacy of every-other-day dosing of NEPA administered during chemomobilization in patients with relapsed-refractory aggressive non-Hodgkin's lymphoma. Eighty-one patients participated. RESULTS Response rates were 77.8% for complete response (no emesis and no rescue use), 72.8% for complete control (complete response and no more than mild nausea), 86.4% for no emesis, and 82.7% for no rescue use during the overall phase (duration of chemomobilization through 48 h after). NEPA was well tolerated with no treatment-related adverse events reported. CONCLUSION NEPA, administered with a simplified every-other-day schedule, show to be very effective in preventing CINV in patients at high risk of CINV undergoing to chemomobilization of hematopoietic stem cells prior to ASCT.

中文翻译：

---

netupitant/帕洛诺司琼联合用药 (NEPA) 在预防自体干细胞移植前接受化学动员的非霍奇金淋巴瘤患者恶心和呕吐方面的疗效和安全性。

目的 预防化疗引起的恶心和呕吐 (CINV) 对于在自体干细胞移植 (ASCT) 前接受高度致吐准备方案的患者来说尤其具有挑战性，因为多天化疗的每日和持续致吐刺激。虽然研究表明在预处理阶段使用含有 NK1 受体拮抗剂 (NK1RA) 的方案可有效预防 CINV，但尚无研究评估在 ASCT 之前的化学动员期间止吐剂的使用。方法 这项多中心、开放标签、IIa 期研究评估了在复发难治性侵袭性非霍奇金淋巴瘤患者化疗期间每隔一天给药一次 NEPA 的疗效。八十一名患者参加。结果响应率为 77。8% 完全缓解（无呕吐和无急救使用），72.8% 完全控制（完全缓解且不超过轻度恶心），86.4% 无呕吐，82.7% 无急救使用在整个阶段（持续时间48 小时后进行化学动员）。NEPA 耐受性良好，未报告与治疗相关的不良事件。结论 NEPA 采用简化的隔日给药方案，显示在预防 ASCT 前接受造血干细胞化学动员的 CINV 高风险患者的 CINV 方面非常有效。